Results 61 to 70 of about 25,148 (309)
Clinical Journal of the American Society of Nephrology, 2011 Renal osteodystrophy (ROD) is one of the three components of chronic kidney disease–mineral and bone disorder (CKD-MBD) ([1][1]). Patients with CKD may develop various types of bone disease, spanning the spectrum of extreme situations such as severe osteitis fibrosa, osteomalacia, mixed ...
Tilman B, Drüeke +1 more
openaire +2 more sources
Antitumor Effect of Sclerostin against Osteosarcoma [PDF]
Cancers, 2021 Various risk factors and causative genes of osteosarcoma have been reported in the literature; however, its etiology remains largely unknown. Bone formation is a shared phenomenon in all types of osteosarcomas, and sclerostin is an extracellular soluble factor secreted by osteocytes that prevents bone formation by inhibiting the Wnt signaling pathway ...
Hirokazu Ideta +17 more
openaire +2 more sources
Sclerostin expression in skeletal sarcomas [PDF]
Human Pathology, 2016 Sclerostin (SOST) is an extracellular Wnt signaling antagonist which negatively regulates bone mass. Despite this, the expression and function of SOST in skeletal tumors remain poorly described. Here, we first describe the immunohistochemical staining pattern of SOST across benign and malignant skeletal tumors with bone or cartilage matrix (n=68 ...
Shen, Jia +13 more
openaire +4 more sources
Science Translational Medicine, 2020 SOST variants that mimic therapeutic inhibition of sclerostin for osteoporosis are associated with higher risk of cardiovascular disease. Safety and sclerostin Antibodies that inhibit sclerostin are used to treat osteoporosis because they increase bone ...
Jonas Bovijn +19 more
semanticscholar +1 more source
Sclerostin as a biomarker of physical exercise in osteoporosis: A narrative review
Frontiers in Endocrinology, 2022 Osteoporosis, a disease of low bone mass, is characterized by reduced bone mineral density (BMD) through abnormalities in the microarchitecture of bone tissue.
A. Oniszczuk +7 more
semanticscholar +1 more source
BMC Musculoskeletal Disorders, 2021 Background Wnt-catenin signaling antagonists sclerostin and dickkopf-related protein-1 (Dkk-1) inhibit bone formation and are involved in the pathogenesis of postmenopausal osteoporosis (PO). However, the association between sclerostin and Dkk-1 and bone
Jia Peng +5 more
doaj +1 more source
The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction [PDF]
Journal of Medical Biochemistry, 2020 Background: The aim of this study was to compare serum sclerostin concentrations in patients with thyroid dysfunction with euthyroid control subjects and to assess the relationship between sclerostin and markers of bone metabolism (osteocalcin and beta ...
Mihaljević Olgica +8 more
doaj
Positioning novel biologicals in CKD-mineral and bone disorders [PDF]
, 2017 Renal osteodystrophy (ROD), the histologic bone lesions of chronic kidney disease (CKD), is now included in a wider syndrome with laboratory abnormalities of mineral metabolism and extra-skeletal calcifications or CKD-mineral and bone disorders (CKD-MBD),
Covic, Adrian +5 more
core +1 more source
Sclerostin Protects Against Vascular Calcification Development in Mice
Journal of Bone and Mineral Research, 2021 Sclerostin is a negative regulator of the Wnt/β‐catenin signaling and is, therefore, an important inhibitor of bone formation and turnover. Because ectopic vascular calcification develops in a similar way to bone formation, one might reasonably attribute
Annelies De Maré +4 more
semanticscholar +1 more source
Sclerostin as Regulatory Molecule in Vascular Media Calcification and the Bone–Vascular Axis
Toxins, 2019 Sclerostin is a well-known inhibitor of bone formation that acts on Wnt/β-catenin signaling. This manuscript considers the possible role of sclerostin in vascular calcification, a process that shares many similarities with physiological bone ...
Annelies De Maré +7 more
doaj +1 more source